🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

624 results for “Solid” Clear

  1. Association atezolizumab + BDB001 + RT

    Eikon Therapeutics

    Solid Tumor, Adult

    phase 2 small molecule active

    1 trial

  2. Autologous Tumor Infiltrating Lymphocytes MDA-TIL

    Iovance Biotherapeutics B.V.

    Malignant Solid Neoplasm

    phase 2 mab terminated

    1 trial

  3. Avapritinib, Avapritinib, Avapritinib

    Blueprint Medicines (Netherlands) B.V.

    Solid Tumors Dependent on KIT or PDGFRA Signaling

    phase 2 small molecule active

    1 trial

  4. BAY 2927088 Bayer (CM), BAY 2927088 Bayer (CM), BAY 2927088, BAY 2927088 Bayer

    Bayer AG

    HER2 mutation, Advanced solid tumors

    phase 2 small molecule active

    1 trial

  5. BAY 3713372 Bayer, BAY 3713372 Bayer, -, -, -, -

    Bayer AG

    MTAP-deleted Solid Tumors

    phase 2 small molecule active

    1 trial

  6. BAY 73-4506, AVELUMAB

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Adult patients with advanced or metastatic solid tumors

    phase 2 small molecule active

    1 trial

  7. BAY 73-4506, BAY 734506

    Bayer AG

    Solid malignant tumors

    phase 2 small molecule active

    1 trial

  8. BDB001

    Eikon Therapeutics

    Tumor, Solid

    phase 2 small molecule completed

    1 trial

  9. BDC-1001

    Bolt Biotherapeutics

    HER2-positive Solid Tumors

    phase 2 small molecule terminated

    1 trial

  10. BI 1810631

    Boehringer Ingelheim International GmbH

    HER2-mutated or overexpressed/amplified solid tumours

    phase 2 small molecule active

    1 trial

  11. BI 907828, BI 907828, BI 907828

    Boehringer Ingelheim International GmbH

    Solid tumours

    phase 2 small molecule active

    1 trial

  12. BI 907828, Ezabenlimab, BI 907828, BI 907828

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Adult patients with locally advanced/metastatic solid tumors

    phase 2 small molecule active

    1 trial

  13. BMS-986517

    Bristol-Myers Squibb / Pfizer EEIG

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  14. BMS-986523, BMS-986523

    Bristol-Myers Squibb / Pfizer EEIG

    Advanced Solid Tumor Malignancies

    phase 2 small molecule active

    1 trial

  15. BNT142

    BioNTech Manufacturing GmbH

    Solid Tumors

    phase 2 small molecule active

    1 trial

  16. BNT327 1-15, BNT327, BNT326

    BioNTech Manufacturing GmbH

    Advanced solid tumors

    phase 2 small molecule active

    1 trial

  17. BNT329

    BioNTech Manufacturing GmbH

    Advanced Solid Cancers

    phase 2 small molecule active

    1 trial

  18. BRIGATINIB, Alunbrig 180 mg film-coated tablets, Alunbrig 90 mg film-coated tablets, Alunbrig 30 mg film-coated tablets

    AXIM BIOTECHNOLOGIES, INC.

    Anaplastic Large Cell Lymphoma (ALCL), Inflammatory Myofibroblastic Tumors (IMT), Other solid tumors

    phase 2 small molecule active

    1 trial

  19. BT1718

    BICYCLE THERAPEUTICS

    Advanced Solid Tumours

    phase 2 small molecule completed

    1 trial

  20. Balugrastim

    Teva Pharma GmbH

    Solid Tumors

    phase 2 small molecule terminated

    1 trial

  21. Bemarituzumab

    Amgen Technology (Ireland) UC

    Solid tumours

    phase 2 small molecule active

    1 trial

  22. Bevacizumab/Irinotecan

    Solid Biosciences

    Glioblastoma

    phase 2 small molecule completed

    1 trial

  23. CAMPTO 20 mg/mL concentrate for solution for infusion, Futibatinib, Leucovorin-Teva 10 mg/ml Concentrate for Solution for Infusion, FLUOROURACIL, CISPLATIN, OXALIPLATIN, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Taiho Pharma Netherlands B.V.

    Solid Tumors

    phase 2 small molecule active

    1 trial

  24. CEA CAR-T cells

    PRECISION BIOSCIENCES INC

    Solid Tumor

    phase 2 mab active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources